Schizophrenia Clinical Trial
Official title:
The Effect of a Community-based Long-acting Antipsychotic-treated Management Model on the Violence Risk of Patients With Schizophrenia: a 1-year, Open-label Randomized Controlled Study
This is a 12-month open-label randomized controlled study. Patients with schizophrenia and
violence risk under the government supervision will be enrolled in the study. A
community-based long-acting antipsychotics-treated management model will be applied to the
experimental group, which means that professional psychiatrists will provide guidance to
primary-level mental health workers on the psychotic treatment, and monthly-injected
long-acting antipsychotic, paliperidone palmitate, will be used in the schizophrenia
treatment. Every subject in experimental group will be equipped with an intelligent robot
capable at push-to-talk and push-to-view, allowing the patients and caregivers to contact
doctors for assistance at any time.
The subjects in experimental group will be injected with 150mg eq and 100mg eq paliperidone
palmitate in the deltoid at the 1st and 8th day, and afterwards a flexible dose of
paliperidone palmitate from 75 to 150mg eq will be administrated monthly according to
clinical judgement.
Subjects in control group will be treated with oral antipsychotics or other conventional
medication.
Status | Not yet recruiting |
Enrollment | 150 |
Est. completion date | April 2018 |
Est. primary completion date | April 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Diagnosed as schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders , Fifth Edition (DSM-V) and rated under 70 in PANSS; - Had violent behavior such as smashing or breaking, threatening with a weapon, commiting arson or explosion in the past one year, whether the behavior can be stopped by persuading or not; - Living with a guardian or a caregiver; - Informed consent from the patients or their guardians; - Resulted negative in urine pregnancy test if female at their reproductive age; female subjects must take effective measures to prevent pregnancy during the whole study or have been postmenopausal. Exclusion Criteria: - Patients who have had suicidal ideation or suicidal attempts within 12 months before screening or in screening period; - Intravenous drug abuse or Opioid dependence within 3 months before screening; - Patients with treatment-resistant schizophrenia; - Large dose of Clozapine (=200mg/day) or other long-acting injectable antipsychotics used within 3 months or within 2 drug half-life periods before screening; - Patients with any severe or unstable cardiovascular, respiratory, nervous system or other system diseases; clinically significant abnormality in laboratory examinations or ECG; - Communication difficulties caused by cognitive impairment or unable to complete the assessments in the study; - Patients assessed as unsuitable for the study in other reasons, such as allergic or intolerant to risperidone or paliperidone, resistant to risperidone or paliperidone (ineffective after adequate dosage and duration in medical history); unable to provide informed consent; historical treatments which might effect the results of the study; historical neuroleptic malignant syndrome or tardive dyskinesia. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Maosheng Fang |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Violence Risk Assessment For Severe Psychiatric Patients | The percentage of subjects rated as no or low risk (scored 0 or 1) in Violence Risk Assessment For Severe Psychiatric Patients after 1-year treatment | 1 year | |
Secondary | Modified Overt Aggression Scale (MOAS) | Patients' rated score in Modified Overt Aggression Scale after 1-year treatment | 1 year | |
Secondary | Health economic evaluation | The patients' and the caregivers' health economic questionnaire after 1-year treatment | 1 year | |
Secondary | Positive and Negative Syndrome Scale (PANSS) | PANSS total score after 6-month and 1-year treatment | 1 year | |
Secondary | Hospitalization frequency | Hospitalization frequency after 6-month and 1-year treatment | 1 year | |
Secondary | WHO Quality of Life-BREF (WHOQOL-BREF) | The patients' and the caregivers' WHOQOL-BREF score after 6-month and 1-year treatment | 1 year | |
Secondary | Visual Analogue Scale-100 (VAS 100) | The patients' and the caregivers' VAS 100 score after 6-month and 1-year treatment | 1 year | |
Secondary | Family Burden Scale of Diseases (FBS) | Family burden of the patient's family | 1 year | |
Secondary | Personal and Social Performance Scale (PSP) | PSP global score after 6-month and 1-year treatment | 1 year | |
Secondary | Treatment Emergent Symptom Scale (TESS) | Treatment Emergent Symptom Scale (TESS) score after 6-month and 1-year treatment | 1 year | |
Secondary | Vital signs | Heart rate and blood pressure after 6-month and 1-year treatment | 1 year | |
Secondary | Clinical laboratory examination | Blood routine examination after 6-month and 1-year treatment | 1 year | |
Secondary | Electrocardiogram (ECG) | Electrocardiogram (ECG) after 6-month and 1-year treatment | 1 year | |
Secondary | Adverse events | The frequency of adverse events in the treatment period | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |